CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The disappointing findings from the $100 million National Institutes of Health (NIH) project, the first-ever prevention trial for Alzheimer’s disease, which tested an antiamyloid monoclonal antibody called crenezumab in people with the Paisa mutation, the most common cause of familial, early-onset Alzheimer’s disease.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
